CRDF (Cardiff Oncology) Institutional Ownership: 41.41% (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRDF Cardiff Oncology Inc CRDF
48 GF Score
Price $0.89
GF Value $1.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Institutional Ownership?

Cardiff Oncology CRDF -33.63% 48 Institutional Ownership is 41.41% as of Jul. 15, 2026. GuruFocus rates CRDF with a GF Score™ of 48/100 and a GF Value™ of $1.40 (Possible Value Trap). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cardiff Oncology's institutional ownership is 41.41%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cardiff Oncology's Insider Ownership is 3.84%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cardiff Oncology's Float Percentage Of Total Shares Outstanding is 97.65%.

Cardiff Oncology Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Institutional Ownership Chart

Cardiff Oncology Historical Data

The historical data trend for Cardiff Oncology can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 20.06 19.81 19.67 21.92 21.67 21.69 21.08 20.58 20.50 17.03
CRDF
48GF Score
Cardiff Oncology Inc CRDF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 41.41% mean?
Cardiff Oncology (CRDF) has a Institutional Ownership of 41.41% as of Jul. 15, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cardiff Oncology and its competitors.
Is Cardiff Oncology's Institutional Ownership too high?
Cardiff Oncology's current Institutional Ownership is 41.41%. Overall, Cardiff Oncology has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Institutional Ownership compare to MAIA and TELO?
Cardiff Oncology's Institutional Ownership of 41.41% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current Institutional Ownership is 41.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.40, compared to a current price of $0.89 — trading 36.5% below its estimated fair value. The current Institutional Ownership is 41.41%. Cardiff Oncology's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Institutional Ownership is 41.41% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $0.89 is trading 36.5% below its estimated GF Value™ of $1.40. GuruFocus considers Cardiff Oncology to be Possible Value Trap.

Key valuation signals for CRDF:

  • Institutional Ownership: 41.41%
  • GF Value™: $1.40 vs. price of $0.89 (36.5% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
48GF Score

Get the complete analysis for CRDF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.89
Price
$1.40
GF Value